Seeking Alpha

Oncolytics Biotech (ONCY -0.7%) announces preliminary results from a Phase I study examining the...

Oncolytics Biotech (ONCY -0.7%) announces preliminary results from a Phase I study examining the intravenous administration of Reolysin in combination with Folfiri in patients with metastatic colorectal cancer, saying the combination was safe and well tolerated and resulted in disease control in the majority of evaluable patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|